

# Nancy J Brown

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1009541/publications.pdf>

Version: 2024-02-01

100  
papers

4,637  
citations

117625

34  
h-index

102487

66  
g-index

121  
all docs

121  
docs citations

121  
times ranked

6165  
citing authors

#	ARTICLE	IF	CITATIONS
1	The soluble epoxide hydrolase inhibitor GSK2256294 decreases the proportion of adipose pro-inflammatory T cells. Prostaglandins and Other Lipid Mediators, 2022, 158, 106604.	1.9	0
2	DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment. Hypertension, 2022, 79, 827-835.	2.7	6
3	Association of a glucagon-like peptide-1 receptor gene variant with glucose response to a mixed meal. Diabetes, Obesity and Metabolism, 2021, 23, 281-286.	4.4	13
4	Connecting Generations of Scientists in the Council on Hypertension Through Harriet Dustan. Hypertension, 2021, 77, 296-307.	2.7	0
5	Treatment of Primary Aldosteronism Increases Plasma Epoxyeicosatrienoic Acids. Hypertension, 2021, 77, 1323-1331.	2.7	2
6	Active B-Type Natriuretic Peptide Measured by Mass Spectrometry and Response to Sacubitril/Valsartan. Journal of Cardiac Failure, 2021, 27, 1231-1239.	1.7	8
7	Association of Apparent Treatment-Resistant Hypertension With Differential Risk of End-Stage Kidney Disease Across Racial Groups in the Million Veteran Program. Hypertension, 2021, 78, 376-386.	2.7	2
8	GSK2256294 Decreases sEH (Soluble Epoxide Hydrolase) Activity in Plasma, Muscle, and Adipose and Reduces F2-Isoprostanes but Does Not Alter Insulin Sensitivity in Humans. Hypertension, 2021, 78, 1092-1102.	2.7	9
9	Sitagliptin Decreases Visceral Fat and Blood Glucose in Women With Polycystic Ovarian Syndrome. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 136-151.	3.6	27
10	Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. Analytical Chemistry, 2020, 92, 859-866.	6.5	10
11	MO045 MITOCHONDRIAL DYSFUNCTION AND MUSCLE ENERGETICS IN CKD PATIENTS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	0
12	Retrospective cohort study to characterise the blood pressure response to spironolactone in patients with apparent therapy-resistant hypertension using electronic medical record data. BMJ Open, 2020, 10, e033100.	1.9	5
13	Exome Sequencing Reveals Common and Rare Variants in <i>F5</i> Associated With ACE Inhibitor and Angiotensin Receptor Blocker-Induced Angioedema. Clinical Pharmacology and Therapeutics, 2020, 108, 1195-1202.	4.7	18
14	Response to Letter to the Editor: "Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin". Journal of the Endocrine Society, 2020, 4, bvaa006.	0.2	0
15	Skeletal Muscle Mitochondrial Dysfunction Is Present in Patients with CKD before Initiation of Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 926-936.	4.5	68
16	SUN-544 Immunologic Effects of GLP-1 Activation in Obese Adipose Tissue. Journal of the Endocrine Society, 2020, 4, .	0.2	0
17	Dipeptidyl Peptidase 4 Inhibition Increases Postprandial Norepinephrine via Substance P (NK1 Receptor) During RAAS Inhibition. Journal of the Endocrine Society, 2019, 3, 1784-1798.	0.2	12
18	Adipose Tissue in Persons With HIV Is Enriched for CD4+ T Effector Memory and T Effector Memory RA+ Cells, Which Show Higher CD69 Expression and CD57, CX3CR1, GPR56 Co-expression With Increasing Glucose Intolerance. Frontiers in Immunology, 2019, 10, 408.	4.8	31

#	ARTICLE	IF	CITATIONS
19	Mineralocorticoid Receptor Activation and Atrial Fibrosis. <i>Hypertension</i> , 2019, 73, 294-295.	2.7	1
20	Early urine electrolyte patterns in patients with acute heart failure. <i>ESC Heart Failure</i> , 2019, 6, 80-88.	3.1	27
21	Transformation to academic leadership: The role of mentorship and executive coaching.. <i>Consulting Psychology Journal</i> , 2019, 71, 141-160.	0.8	16
22	MON-474 Dipeptidyl Peptidase-4 (DPP4) Inhibition Decreases Visceral Fat and Improves Glucose Metabolism in Overweight Women with Polycystic Ovarian Syndrome. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	1
23	OR05-6 The Effect of the GLP1R Variant rs6923761 on Post-Prandial Glucose Levels during Treatment with Sitagliptin. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.2	2
24	Higher urinary cortisol levels associate with increased cardiovascular risk. <i>Endocrine Connections</i> , 2019, 8, 634-640.	1.9	7
25	Dipeptidyl Peptidase-4 Inhibition Potentiates Stimulated Growth Hormone Secretion and Vasodilation in Women. <i>Journal of the American Heart Association</i> , 2018, 7, .	3.7	7
26	The Vasculature in Prediabetes. <i>Circulation Research</i> , 2018, 122, 1135-1150.	4.5	91
27	Two Pools of Epoxyeicosatrienoic Acids in Humans. <i>Hypertension</i> , 2018, 71, 346-355.	2.7	9
28	Fish Oil and Perioperative Bleeding. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004584.	2.2	36
29	Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study. <i>BMJ Open</i> , 2018, 8, e021640.	1.9	15
30	Developing Physician-Scientists. <i>Circulation Research</i> , 2018, 123, 645-647.	4.5	10
31	Endogenous bradykinin and B1-B5 during angiotensin-converting enzyme inhibitor-associated angioedema. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 142, 1636-1639.e5.	2.9	18
32	DPP (Dipeptidyl Peptidase)-4 Inhibition Potentiates the Vasoconstrictor Response to NPY (Neuropeptide) Tj ETQq0.0.0 rgBT /Overlock 1	2.7	21
33	Aprepitant for the Treatment of Pruritus in Sjögren Syndrome. <i>JAMA Dermatology</i> , 2018, 154, 1221.	4.1	19
34	The Cardiovascular Effects of Peptidase Inhibition. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PL-3.	0.0	0
35	Mineralocorticoid Receptor Blockers and Aldosterone Synthase Inhibitors. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, SY39-3.	0.0	0
36	Muscle mitochondrial dysfunction at different stages of chronic kidney disease (CKD). <i>FASEB Journal</i> , 2018, 32, 908.2.	0.5	0

#	ARTICLE	IF	CITATIONS
37	Pharmacogenomics of off-target adverse drug reactions. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1896-1911.	2.4	48
38	Effect of bradykinin receptor antagonism on ACE inhibitor-associated angioedema. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 242-248.e2.	2.9	73
39	Angiotensin-converting Enzyme Inhibitor and Other Drug-associated Angioedema. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 483-495.	1.9	35
40	Hypertension and Type 2 Diabetes Are Associated With Decreased Inhibition of Dipeptidyl Peptidase-4 by Sitagliptin. <i>Journal of the Endocrine Society</i> , 2017, 1, 1168-1178.	0.2	18
41	Genetic Effects on the Correlation Structure of CVD Risk Factors: Exome-Wide Data From a Ghanaian Population. <i>Global Heart</i> , 2017, 12, 133.	2.3	4
42	Association of gain-of-function EPHX2 polymorphism Lys55Arg with acute kidney injury following cardiac surgery. <i>PLoS ONE</i> , 2017, 12, e0175292.	2.5	19
43	Response by Hubers and Brown to Letter Regarding Article, "Combined Angiotensin Receptor Antagonism and Nephilysin Inhibition". <i>Circulation</i> , 2016, 134, e11-2.	1.6	0
44	B-Type Natriuretic Peptide, Aldosterone, and Fluid Management in ARDS. <i>Chest</i> , 2016, 150, 102-111.	0.8	17
45	Mitochondrial dysfunction and oxidative stress in patients with chronic kidney disease. <i>Physiological Reports</i> , 2016, 4, e12780.	1.7	156
46	Plasminogen Activator Inhibitor-1 and Diagnosis of the Metabolic Syndrome in a West African Population. <i>Journal of the American Heart Association</i> , 2016, 5, .	3.7	21
47	Examining EXAMINE for an Interaction With Angiotensin-Converting Enzyme Inhibition. <i>Hypertension</i> , 2016, 68, 549-551.	2.7	3
48	Epoxyeicosatrienoic acids and glucose homeostasis in mice and men. <i>Prostaglandins and Other Lipid Mediators</i> , 2016, 125, 2-7.	1.9	28
49	Statins to Reduce Acute Kidney Injury After Cardiac Surgery"Reply. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 349.	7.4	2
50	Heart failure event definitions in drug trials in patients with type 2 diabetes. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 294-296.	11.4	26
51	High-Dose Perioperative Atorvastatin and Acute Kidney Injury Following Cardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 877.	7.4	200
52	Combined Angiotensin Receptor Antagonism and Nephilysin Inhibition. <i>Circulation</i> , 2016, 133, 1115-1124.	1.6	173
53	Cardiovascular Disease Risk Factors in Ghana during the Rural-to-Urban Transition: A Cross-Sectional Study. <i>PLoS ONE</i> , 2016, 11, e0162753.	2.5	41
54	Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis " a randomized cross-over study. <i>BMC Nephrology</i> , 2015, 16, 167.	1.8	18

#	ARTICLE	IF	CITATIONS
55	Phenotype-Driven Plasma Biobanking Strategies and Methods. <i>Journal of Personalized Medicine</i> , 2015, 5, 140-152.	2.5	15
56	Oxidative Stress Biomarkers and Incidence of Postoperative Atrial Fibrillation in the Omega-3 Fatty Acids for Prevention of Postoperative Atrial Fibrillation (OPERA) Trial. <i>Journal of the American Heart Association</i> , 2015, 4, .	3.7	43
57	American Heart Association Cardiovascular Genome-Phenome Study. <i>Circulation</i> , 2015, 131, 100-112.	1.6	26
58	Treatment with Sildenafil Improves Insulin Sensitivity in Prediabetes: A Randomized, Controlled Trial. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 4533-4540.	3.6	61
59	A prevalent caveolin-1 gene variant is associated with the metabolic syndrome in Caucasians and Hispanics. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 1674-1681.	3.4	31
60	Dietary Sodium Restriction Decreases Insulin Secretion Without Affecting Insulin Sensitivity in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014, 99, E1895-E1902.	3.6	25
61	Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. <i>Prostaglandins and Other Lipid Mediators</i> , 2014, 113-115, 38-44.	1.9	36
62	Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition. <i>Hypertension</i> , 2014, 63, 951-957.	2.7	62
63	Dipeptidyl Peptidase 4 Inhibition and the Vascular Effects of Glucagon-Like Peptide-1 and Brain Natriuretic Peptide in the Human Forearm. <i>Journal of the American Heart Association</i> , 2014, 3, .	3.7	28
64	Hypertension Is Associated With Preamyloid Oligomers in Human Atrium: A Missing Link in Atrial Pathophysiology?. <i>Journal of the American Heart Association</i> , 2014, 3, e001384.	3.7	16
65	Quantitative Imaging of Preamyloid Oligomers, a Novel Structural Abnormality, in Human Atrial Samples. <i>Journal of Histochemistry and Cytochemistry</i> , 2014, 62, 479-487.	2.5	13
66	Genetic variation in CYP4A11 and blood pressure response to mineralocorticoid receptor antagonism or ENaC inhibition: an exploratory pilot study in African Americans. <i>Journal of the American Society of Hypertension</i> , 2014, 8, 475-480.	2.3	42
67	Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. <i>Nature Reviews Nephrology</i> , 2013, 9, 459-469.	9.6	290
68	Developing physician-scientists: a perspective. <i>Transactions of the American Clinical and Climatological Association</i> , 2013, 124, 218-29.	0.5	3
69	Cardiovascular effects of antidiabetic agents: focus on blood pressure effects of incretin-based therapies. <i>Journal of the American Society of Hypertension</i> , 2012, 6, 163-168.	2.3	31
70	Patient-Oriented Research in the Era of Personalized Medicine. <i>Clinical and Translational Science</i> , 2012, 5, 119-120.	3.1	0
71	Combined angiotensin-converting enzyme inhibition and receptor blockade associate with increased risk of cardiovascular death in hemodialysis patients. <i>Kidney International</i> , 2011, 80, 978-985.	5.2	61
72	This is not Dr. Conn's aldosterone anymore. <i>Transactions of the American Clinical and Climatological Association</i> , 2011, 122, 229-43.	0.5	8

#	ARTICLE	IF	CITATIONS
73	Interactive Hemodynamic Effects of Dipeptidyl Peptidase-IV Inhibition and Angiotensin-Converting Enzyme Inhibition in Humans. <i>Hypertension</i> , 2010, 56, 728-733.	2.7	137
74	Review: Therapeutic potential of plasminogen activator inhibitor-1 inhibitors. <i>Therapeutic Advances in Cardiovascular Disease</i> , 2010, 4, 315-324.	2.1	43
75	Dipeptidyl Peptidase-IV Inhibitor Use Associated With Increased Risk of ACE Inhibitor-Associated Angioedema. <i>Hypertension</i> , 2009, 54, 516-523.	2.7	200
76	Aldosterone and Vascular Inflammation. <i>Hypertension</i> , 2008, 51, 161-167.	2.7	211
77	Response to Interleukin-6 Antagonists for the Management of Hypertension. <i>Hypertension</i> , 2007, 49, .	2.7	0
78	Endogenous NO Regulates Plasminogen Activator Inhibitor-1 During Angiotensin-Converting Enzyme Inhibition. <i>Hypertension</i> , 2006, 47, 441-448.	2.7	9
79	Contribution of Coagulation Pathways and Fibrinolysis in Generation of Kinins.. <i>Blood</i> , 2006, 108, 1625-1625.	1.4	0
80	Aldosterone and end-organ damage. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 235-241.	2.0	247
81	Loss of normal dietary sodium blood pressure response to angiotensin ii infusion in human essential hypertension. <i>American Journal of Hypertension</i> , 2004, 17, S159.	2.0	0
82	Eplerenone. <i>Circulation</i> , 2003, 107, 2512-2518.	1.6	143
83	ACE Inhibition Versus Angiotensin Type 1 Receptor Antagonism. <i>Hypertension</i> , 2002, 40, 859-865.	2.7	85
84	Dipeptidyl Peptidase IV Activity in Patients With ACE-Inhibitor-Associated Angioedema. <i>Hypertension</i> , 2002, 39, 460-464.	2.7	106
85	The Renin-Angiotensin-Aldosterone System and Fibrinolysis in Progressive Renal Disease. <i>Seminars in Nephrology</i> , 2002, 22, 399-406.	1.6	44
86	Aldosterone and PAI-1: implications for renal injury. <i>Journal of Nephrology</i> , 2002, 15, 230-5.	2.0	22
87	Possible Medication Errors in Home Healthcare Patients. <i>Journal of the American Geriatrics Society</i> , 2001, 49, 719-724.	2.6	125
88	Interactive Effect of PAI-14G/5G Genotype and Salt Intake on PAI-1 Antigen. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1071-1077.	2.4	33
89	Preprescription Genotyping. <i>Circulation</i> , 2001, 103, 1608-1610.	1.6	27
90	Plasminogen Activator Inhibitor-1 Deficiency Prevents Hypertension and Vascular Fibrosis in Response to Long-term Nitric Oxide Synthase Inhibition. <i>Circulation</i> , 2001, 104, 839-844.	1.6	158

#	ARTICLE	IF	CITATIONS
91	Human $\beta_2$ -adrenergic receptor polymorphisms: No association with essential hypertension in black or white Americans. <i>Clinical Pharmacology and Therapeutics</i> , 2000, 67, 670-675.	4.7	70
92	Bradykinin Stimulates Tissue Plasminogen Activator Release From Human Forearm Vasculature Through B <sub>2</sub> Receptor-Dependent, NO Synthase-Independent, and Cyclooxygenase-Independent Pathway. <i>Circulation</i> , 2000, 102, 2190-2196.	1.6	168
93	Bradykinin Stimulates Tissue Plasminogen Activator Release in Human Vasculature. <i>Hypertension</i> , 1999, 33, 1431-1435.	2.7	147
94	Angiotensin II type I Receptor polymorphism in African Americans lower frequency of the C1166 variant. <i>IUBMB Life</i> , 1997, 43, 227-231.	3.4	7
95	Coadministration of glyburide and minoxidil, drugs with opposing effects on potassium channels*. <i>Clinical Pharmacology and Therapeutics</i> , 1997, 61, 662-668.	4.7	2
96	Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin. <i>Thrombosis and Haemostasis</i> , 1997, 77, 522-525.	3.4	128
97	Angiotensin converting enzyme inhibitor-associated angioedema: higher risk in blacks than whites. <i>Pharmacoepidemiology and Drug Safety</i> , 1996, 5, 149-154.	1.9	39
98	Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema*. <i>Clinical Pharmacology and Therapeutics</i> , 1996, 60, 8-13.	4.7	297
99	A pharmacodynamic interaction between caffeine and phenylpropanolamine. <i>Clinical Pharmacology and Therapeutics</i> , 1991, 50, 363-371.	4.7	24
100	Improving the medical record for clinical oncology research by adaptation to a microcomputer. <i>Medical and Pediatric Oncology</i> , 1983, 11, 352-357.	1.0	1